Jonathan Lal, Angela Brand (both active in the Medical Platform of ITFoM), Tobias Schulte in den Bäumen, and Servaas Morre have developed a new model for the valorization of Genome-based Technologies in Public Health.
The article published in the Journal of Translational Medicine can be found here.
An excerpt from the abstract:
- Background -
The success rate of timely translation of genome-based technologies to commercially feasible products/services with applicability in health care systems is significantly low. We identified both industry and scientists neglect health policy aspects when commercializing their technology, more specifically, Public Health Assessment Tools (PHAT) and early on involvement of decision makers through which market authorization and reimbursements are dependent. While Technology Transfer (TT) aims to facilitate translation of ideas into products, Health Technology Assessment, one component of PHAT, for example, facilitates translation of products/processes into healthcare services and eventually comes up with recommendations for decision makers. We aim to propose a new model of valorization to optimize integration of genome-based technologies into the healthcare system.
Read the full abstract on the website of the Journal of Translational Medicine.
Download the PDF here